​

Janux Therapeutics Stock (NASDAQ:JANX)

ForecastRevenueOwnershipFinancialsChart
Janux Therapeutics by TradingView

Previous Close

$24.90

52W Range

$21.73 - $71.71

50D Avg

$24.40

200D Avg

$28.34

Market Cap

$1.64B

Avg Vol (3M)

$832.15K

Beta

2.82

Div Yield

-

JANX Company Profile

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

91

IPO Date

Jun 11, 2021

Website

JANX Performance

JANX Financial Summary

Dec 24Dec 23Dec 22
Revenue$10.59M$8.08M$8.61M
Operating Income$-98.85M$-72.98M$-67.09M
Net Income$-68.99M$-58.29M$-54.15M
EBITDA$-98.85M$-71.02M$-66.25M
Basic EPS$-1.28$-1.32$-1.31
Diluted EPS$-1.28$-1.32$-1.31

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
IMTXImmatics N.V.
RCUSArcus Biosciences, Inc.
ABCLAbCellera Biologics Inc.
CLDXCelldex Therapeutics, Inc.
ZYMEZymeworks Inc.
GPCRStructure Therapeutics Inc.
EWTXEdgewise Therapeutics, Inc.
MNKDMannKind Corporation
VRDNViridian Therapeutics, Inc.
HRMYHarmony Biosciences Holdings, Inc.